{"id":369,"date":"2018-12-16T22:19:49","date_gmt":"2018-12-16T22:19:49","guid":{"rendered":"http:\/\/beasleypharmabio.com\/?page_id=369"},"modified":"2019-07-20T15:00:58","modified_gmt":"2019-07-20T19:00:58","slug":"publications-and-patents-4-2-2","status":"publish","type":"page","link":"https:\/\/beasleypharmabio.com\/?page_id=369","title":{"rendered":"Publications and Patents"},"content":{"rendered":"
\n\t
\n\t\t
\n\t\t
\n\t\t\t

BOOK CHAPTERS<\/h3>\n
    \n
  1. Beasley C, Grundy S, Gannon K, Berg P<\/span>
    \nOverview of the safety of olanzapine<\/strong>
    \nIn Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
    \nOlanzapine (Zyprexa): A Novel Antipsychotic<\/em>
    \nPhiladelphia: Lippincott Williams & Wilkins, 2000<\/li>\n
  2. Tran P. Sutton V, Beasley C, Tollefson G<\/span>
    \nEfficacy of olanzapine<\/strong>
    \nIn Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
    \nOlanzapine (Zyprexa): A Novel Antipsychotic<\/em>
    \nPhiladelphia: Lippincott Williams & Wilkins, 2000<\/li>\n
  3. Anderson J, Kline P, Beasley C<\/span>
    \nA general learning theory and its application to schema abstraction
    \n<\/strong>In Bower G (Ed.)
    \nThe Psychology of Learning and Motivation, Vol 13<\/em>.
    \nNew York: Academic Press, 1979<\/li>\n
  4. Anderson J, Kline P, Beasley C<\/span>
    \nComplex learning processes
    \n<\/strong>In Snow R, Federico P & Montague W (Eds.)
    \nAptitude, Learning, and Instruction, Vol 2: Cognitive Process Analysis of Learning and Problem Solving<\/em>
    \nHillsdale, NJ: Lawrence Erlbaum and Associates, 1980<\/li>\n<\/ol>\n\n\t\t<\/div> \n\t<\/div>
    <\/div>\n
    \n\t\t
    \n\t\t\t

    ARTICLES<\/h3>\n
      \n
    1. Beasley CM Jr, Crowe B, Nilsson M, Wu L, Tabbey R, Hietpas RT, Dean R, Horn PS<\/span>\n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n
      Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods<\/strong><\/div>\n
      J Biopharm Stat <\/em>29:516-528; 2019<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n
    2. Tumuklu MN, Tumuklu MM, Nesterenko V, Jayathilake K, Beasley CM Jr, Meltzer HY<\/span>
      \n24 hour measures of heart rate corrected QT interval (QTc), peak-to-end of the T-wave (Tpe), and Tpe\/QTc ratio during antipsychotic treatment<\/strong>
      \nJ Clin Psychopharmacol <\/em>39:100-107; 2019<\/li>\n
    3. Beasley CM Jr, Crowe B, Nilsson M, Wu L, Tabbey R, Hietpas RT, Dean R, Horn PS<\/span>
      \nReference limits for outlier analyses in randomized clinical trials<\/strong>
      \nTher Innov Regul Sci <\/em>6:668-737; 2017<\/li>\n
    4. Crowe B, Brueckner A, Beasley C, Kulkarni P<\/span>
      \nCurrent practices, challenges, and statistical issues with product safety labeling<\/strong>
      \nStatistics in Biopharmaceutical Research<\/em> 5:180-193; 2013<\/li>\n
    5. Loghin C, Haber H, Beasley CM, Kothare PA, Kauffman L, April J, jin L, Allen AJ, Mitchell MI<\/span>
      \nEffect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers<\/strong>
      \nBr J Clin Pharmacol<\/em> 75:549-564; 2013<\/li>\n
    6. Beasley C, Benson C, Xia J, Young S, Haber H, Mitchell M, Loghin C<\/span>
      \nSystematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions<\/strong>
      \nPACE<\/em> 34:1116-1127; 2011<\/li>\n
    7. Millen BA, Campbell GM, Beasley CM<\/span>
      \nWeight changes over time in adults treated with oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials<\/strong>
      \nJ Psychopharmacol<\/em> 25:639-645; 2011<\/li>\n
    8. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV<\/span>
      \nSuicidality and risk of suicide \u2013 definition, drug safety concerns, and a necessary target for for drug development: a brief report<\/strong>
      \nJ Clin Psychiatry<\/em> 71:1040-1046; 2010<\/li>\n
    9. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV<\/span>
      \nSuicidality and risk of suicide \u2013 definition, drug safety concerns, and a necessary target for for drug development: a consensus statement<\/strong>
      \nJ Clin Psychiatry<\/em> 71:pe1-pe21; 2010<\/li>\n
    10. Lipkovich I, Jacobson JG, Caldwell C, Hoffman VP, Kryzhanovskaya L, Beasley CM<\/span>
      \nEarly predictors of weight gain risk during treatmentwith olanzapine: analysis of pooled data from 58 clinical trials<\/strong>
      \nPsychopharm Bull<\/em> 42:23-39; 2009<\/li>\n
    11. Beasley CM, Dmitrienko A, Mitchell MI<\/span>
      \nDesign and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings<\/strong>
      \nExpert Rev Clin Pharmacol<\/em> 1:815-839; 2008<\/li>\n
    12. Beasley C, Ball S, Nilsson M, et al<\/span>
      \nFluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials<\/strong>
      \nJ Clin Psychopharmacol<\/em> 27:682-686; 2007<\/li>\n
    13. Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM<\/span>
      \nEvaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for indications other than major depressive disorder<\/strong>
      \nPsychol Med<\/em> 37:1-9; 2007<\/li>\n
    14. Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM, <\/span>
      \nAll-cause treatment discontinuation in schizophrenia during treatmrnt with olanzapine relative to other antipsychotics: an integrated analysis<\/strong>
      \nJ Clin Psychopharmacol<\/em> 27:252-258; 2007<\/li>\n
    15. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M<\/span>
      \nTreatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes<\/strong>
      \nPsychother Psychosom<\/em> 76:40-46; 2007<\/li>\n
    16. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH<\/span>
      \nEarly symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications<\/strong>
      \nJ Clin Psych<\/em> 68:52-57; 2007<\/li>\n
    17. Crumb WJ, Ekins S, Darazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM<\/span>
      \nEffects of Antipsychotic Drugs on Ito<\/sub>, INa<\/sub>, Isus<\/sub>, IK1<\/sub>, and hERG: QT prolongation, atructure activity relationship and network analysis<\/strong>
      \nPharmacol Res<\/em> 23:1133-1143; 2006<\/li>\n
    18. Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D<\/span>
      \nIs quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? <\/strong>
      \nJ Clin Psychopharmacol<\/em> 26:40-44; 2006<\/li>\n
    19. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker JS, Beasley CM<\/span>
      \nEfficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial<\/strong>
      \nJ Sexual Med<\/em> 2:685-698; 2005<\/li>\n
    20. Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turick MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR, Kloner RA<\/span>
      \nThe combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of taalafil on the human QT interval<\/strong>
      \n J Am Coll Cardiol<\/em> 46:678-687; 2005<\/li>\n
    21. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM, Hague JA, Ahuja S<\/span>
      \nTadalafil improved erectile function at 24 and 36 hours after dosing: US trial<\/strong>
      \nJ of Andrology<\/em> 26:310-318; 2005<\/li>\n
    22. Sarazan RD, Crumb WJ, Beasley CM, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ<\/span>
      \nAbsence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5 \u2013 sildenafil, tadalafil, and vardenafil<\/strong>
      \nE J Pharmacology<\/em> 502:163-167; 2004<\/li>\n
    23. Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley C, Emmick J<\/span>
      \nA multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil<\/strong>
      \nEu Urology<\/em> 45:499-507; 2004<\/li>\n
    24. Beasley C, Sutton V, Hamilton S, Walker D, Dossenbach M, Taylor C, Alaka K, Bykowski D, Tollefson G<\/span>
      \nA double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse<\/strong>
      \nJ Clin Psychopharmacol<\/em> 23:582-594; 2003<\/li>\n
    25. Helstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley, CM, Watkins VS<\/span>
      \nTadalafil has no detrimental effect on human spermatogenesis or reproductive hormones<\/strong>
      \nJ Urology<\/em> 170:887-891; 2003<\/li>\n
    26. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM<\/span>
      \nAn integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine<\/strong>
      \nJ Clin Psychiatry<\/em> 64:898-906; 2003<\/li>\n
    27. Lindborg S, Beasley C, Alaka K, Taylor C<\/span>
      \nEffects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients<\/strong>
      \nPsychiatry Res<\/em> 119:113-123; 2003<\/li>\n
    28. Quitkin F, Petkova E, McGrath P, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, ChenY, Klein D<\/span>
      \nWhen should a trial of fluoxetine for major depression be declared failed? <\/strong>
      \nAm J Psychiatry<\/em> 160:734-740; 2003<\/li>\n
    29. Inada T, Beasley C, Tanaka Y, Walker D<\/span>
      \nExtrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol<\/strong>
      \nIntl Clin Psychopharmacol<\/em> 18:39-48; 2003<\/li>\n
    30. Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier, Breier A, Beasley C, Dananberg J<\/span>
      \nHyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or olanzapine. J <\/strong>
      \nClin Endocrinology and Metab<\/em> 87:2918-2923; 2002<\/li>\n
    31. Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C, Feldman P, Mintzer J, Beckett L, Breier A<\/span>
      \nComparison of rapidly acting intramuscular olanzapine, lorazxepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia<\/strong>
      \nNeuropsychopharmacology<\/em> 26:494-504; 2002<\/li>\n
    32. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C<\/span>
      \nFluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment<\/strong>
      \nJ Affect Diord<\/em> 68:243-249; 2002<\/li>\n
    33. Kennedy J, Bymaster F, Schuh L, Calligaro D, Nomikos G, Felder C, Bernauer B, Kinon B, Baker R, Hau D, Roth H, Dossenbach M, Kaiser C, Beasley C, Holcombe J, Effron M, Breier A<\/span>
      \nA current review of olanzapine\u2019s safety in the geriatric patient: from pre-clinical pharmacology to clinical data<\/strong>
      \nInt J Geriatr Psychiatry<\/em> 16:S33-S61; 2001<\/li>\n
    34. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C<\/span>
      \nFluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy<\/strong>
      \nJ Clin Psychopharmacol<\/em> 21:616-618; 2001<\/li>\n
    35. Czekalla J, Beasley C, Dellva M, Berg P, Grundy S<\/span>
      \nAnalysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis<\/strong>
      \nJ Clin Psychiatry<\/em> 62:191-198; 2001<\/li>\n
    36. Czekalla J, Kollack-Walker S, Beasley C<\/span>
      \nCardiac Safety Parameters of Olanzapine: comparison with other atypical and typical antipsychotics<\/strong>
      \nJ Clin Psychiatry<\/em> 62:suppl 2:35-40; 2001<\/li>\n
    37. Czekalla J, Beasley CM, Ditmann RW, Helsberg K, Kollack-Walker S<\/span>
      \nKardiale vertr\u00e4glichkeit unter nueroleptika: vergleichende \u00fcbersicht zu Qtc-parametern und assoziierten effekten unter olanzapin und anderen atypischen sowie typischen antipsychotika<\/strong>
      \nNervenheilkunde<\/em> 20:194-201; 2001<\/li>\n
    38. Perry P, Lund B, Sanger T, Beasley C<\/span>
      \nOlanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial<\/strong>
      \nJ Clin Psychopharmacol<\/em> 21:14-20; 2001<\/li>\n
    39. Beasley C, Koke S, Nilsson M, Gonzales J<\/span>
      \nAdverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis<\/strong>
      \nClin Ther<\/em> 22:1319-1330; 2000<\/li>\n
    40. Voss S, Sanger T, Beasley C<\/span>
      \nHematologic reference ranges in a population of patients with schizophrenia<\/strong>
      \nJ Clin Psychopharmacol<\/em> 20:653-657, 2000<\/li>\n
    41. Beasley C, Nilsson M, Koke S, Gonzales J<\/span>
      \nEfficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg\/day dose<\/strong>
      \nJ Clin Psychiatry<\/em> 61:722-728; 2000<\/li>\n
    42. McGrath P, Stewart J, Petkova E, Quitkin F, Amsterdam J, Fawcett J, Reimherr F, Rosenbaum J, Beasley C<\/span>
      \nPredictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression<\/strong>
      \nJ Clin Psychiatry<\/em> 61:518-524; 2000<\/li>\n
    43. Michelson D, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Zajecka J, Sundell K, Kim Y, Beasley C<\/span>
      \nChanges in Weight During a 1-Year Trial of Fluoxetine<\/strong>
      \nAm J Psychiatry<\/em> 156:1170-1176; 1999<\/li>\n
    44. Revicki D, Genduso L, Hamilton S, Ganoczy D, Beasley C<\/span>
      \nOlanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial<\/strong>
      \nQual Life Res<\/em> 8:417-426; 1999<\/li>\n
    45. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C<\/span>
      \nFluoxetine efficacy in menopausal women with and without estrogen replacement<\/strong>
      \nJ Affect Disord<\/em> 55:11-17; 1999<\/li>\n
    46. Callaghan J, Bergstrom R, Ptak L, Beasley C<\/span>
      \nOlanzapine: pharmacokinetic and pharmacodynamic profile<\/strong>
      \nClin Pharmacokinet<\/em> 37:177-193; 1999<\/li>\n
    47. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C<\/span>
      \nBlood pressure changes during short-term fluoxetine treatment<\/strong>
      \nJ Clin Psychopharmacol<\/em> 19:9-14; 1999<\/li>\n
    48. Zajecka J, Amsterdam J, Quitkin F, Reimberr F, Rosenbaum J, Tamura R, Sundell K, Michelson D, Beasley C<\/span>
      \nChanges in adverse events reported by patients during 6 months of fluoxetine therapy<\/strong>
      \nJ Clin Psychiatry<\/em> 60:389-394; 1999<\/li>\n
    49. Beasley C, Dellva M, Tamura R, Morgenstern H, Glazer W, Ferguson K, Tollefson G<\/span>
      \nRandomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol<\/strong>
      \nBr J Psychiatry<\/em> 174:23-30; 1999<\/li>\n
    50. Tran P, Tollefson G, Sanger T, Lu Y, Berg P, Beasley C<\/span>
      \nOlanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy<\/strong>
      \nBr J Psychiatry<\/em> 174:15-22; 1999<\/li>\n
    51. Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C, Tollefson G<\/span>
      \nOlanzapine versus haloperidol treatment in first episode psychosis<\/strong>
      \nAm J Psychiatry<\/em> 156:79-87; 1999<\/li>\n
    52. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Schweizer E, Beasley C<\/span>
      \nEfficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode<\/strong>
      \nJ Clin Psychopharmacol<\/em> 18:435-440; 1998<\/li>\n
    53. Reimherr F, Amsterdam J, Qutikin F, Rosenbaum J, Fava M, Zajecka J, Beasley C, Michelson D, Roback P, Sundell K<\/span>
      \nOptimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment<\/strong>
      \nAm J Psychiatry<\/em> 155:1247-1253; 1998<\/li>\n
    54. Beasley C<\/span>
      \nOlanzapine: recent clinical findings and increased patient benefits<\/strong>
      \nJapanese J Clin Psychopharmacol<\/em> 1:759-765; 1998<\/li>\n
    55. Tollefson G, Sanger T, Beasley C, Tran P<\/span>
      \nA double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia<\/strong>
      \nBiol Psychiatry<\/em> 43:803-810; 1998<\/li>\n
    56. Tran P, Dellva M, Tollefson G, Wentley A, Beasley C<\/span>
      \nOral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses<\/strong>
      \nBr J Psychiatry<\/em> 172:499-505; 1998<\/li>\n
    57. Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C<\/span>
      \nSafety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study<\/strong>
      \nJ Clin Psychopharmacol<\/em> 18:193-197; 1998<\/li>\n
    58. Stewart J, Quitkin F, McGrath P, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P<\/span>
      \nUse of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo<\/strong>
      \nArch Gen Psychiatry<\/em> 55:334-343; 1998<\/li>\n
    59. Hamilton S, Revicki D, Genduso L, Beasley C<\/span>
      \nOlanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind Trial<\/strong>
      \nNeuropsychopharmacology<\/em> 18:41-49; 1998<\/li>\n
    60. Perry P, Sanger T, Beasley C<\/span>
      \nOlanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients<\/strong>
      \nJ Clin Psychopharmacol<\/em> 17:472-477; 1997<\/li>\n
    61. Dellva M, Tran P, Tollefson G, Wentley A, Beasley C<\/span>
      \nStandard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia<\/strong>
      \nPsychiatric Services<\/em> 48:1571-1577; 1997<\/li>\n
    62. Goldstein D, Hamilton S, Masica D, Beasley C<\/span>
      \nFluoxetine in Medically Stable, Depressed Geriatric Patients: Effects on Weight<\/strong>
      \nJ Clin Psychopharmacol<\/em> 17:365-369; 1997<\/li>\n
    63. Crawford A, Beasley C, Tollefson G<\/span>
      \nThe acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations<\/strong>
      \nSchizophrenia Res<\/em> 26:41-54; 1997<\/li>\n
    64. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C, Tollefson G<\/span>
      \nDouble-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders<\/strong>
      \nJ Clin Psychopharmacol<\/em> 17:407-418; 1997<\/li>\n
    65. Tollefson G, Beasley C, Tamura R, Tran P, Potvin J<\/span>
      \nBlind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol<\/strong>
      \nAm J Psychiatry<\/em> 154:1248-1254; 1997<\/li>\n
    66. Beasley C, Tollefson G, Tran P<\/span>
      \nSafety of olanzapine<\/strong>
      \nJ Clin Psychiatry<\/em> 58:Suppl 10:13-17; 1997<\/li>\n
    67. Beasley C, Tollefson G, Tran P<\/span>
      \nEfficacy of olanzapine: an overview of pivotal clinical trials<\/strong>
      \nJ Clin Psychiatry<\/em> 58:Suppl 10:7-12; 1997<\/li>\n
    68. Blumenfield M, Levy N, Spinowitz B, Charytan C, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R<\/span>
      \nFluoxetine in depressed patients on dialysis<\/strong>
      \nIntl J Psychiatry in Medicine<\/em> 27:71-80; 1997<\/li>\n
    69. Beasley C, Hamilton S, Crawford A, Dellva M, Tollefson G, Tran P, Blin O, Beuzen J<\/span>
      \nOlanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial<\/strong>
      \nEuro Neuropsychopharmacol<\/em> 7:125-137; 1997<\/li>\n
    70. Amsterdam J, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Hornig-Rohan M, Beasley C<\/span>
      \nFluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study<\/strong>
      \nAm J Psychiatry<\/em> 154:963-969; 1997<\/li>\n
    71. Tran P, Dellva M, Tollefson G, Beasley C, Potvin J, Kiesler G<\/span>
      \nExtrapyramidal Symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia<\/strong>
      \nJ Clin Psychiatry<\/em> 58:205-211; 1997<\/li>\n
    72. Tollefson G, Beasley C, Tran P, Street J, Kruger J, Tamura R, Graffeo K, Thieme M<\/span>
      \nOlanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial<\/strong>
      \nAm J Psychiatry<\/em> 154:457-465; 1997<\/li>\n
    73. Beasley C<\/span>
      \nSafety of olanzapine<\/strong>
      \nJ Clin Psychiatry Monograph<\/em> 15:2:19-21; 1997<\/li>\n
    74. Beasley C<\/span>
      \nEfficacy of olanzapine<\/strong>
      \nJ Clin Psychiatry Monograph<\/em> 15:2:17-19; 1997<\/li>\n
    75. Levy N, Blumenfield M, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R<\/span>
      \nFluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function<\/strong>
      \nGen Hosp Psychiatry<\/em> 18:8-13; 1996<\/li>\n
    76. Beasley C, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S<\/span>
      \nOlanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial<\/strong>
      \nPsychopharmacology<\/em> 124:159-167; 1996<\/li>\n
    77. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S<\/span>
      \nOlanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial<\/strong>
      \nNeuropsychopharmacol<\/em> 14:111-123; 1996<\/li>\n
    78. Tollefson G, Rampey A, Beasley C, Enas G, Potvin J<\/span>
      \nAbsence of a relationship between adverse events and suicidality during pharmacotherapy for depression<\/strong>
      \nJ Clin Psychopharmacol<\/em> 14:163-169; 1994<\/li>\n
    79. Tollefson G, Fawcett J, Winokur G, Beasley C, Potvin J, Faries D, Rampey A, Sayler M<\/span>
      \nEvaluation of suicidality during pharmacologic treatment of mood and non-mood disorders<\/strong>
      \nAnn Clin Psychiatry<\/em> 5:209-224; 1993<\/li>\n
    80. Beasley C, Holman S, Potvin J<\/span>
      \nFluoxetine compared with imipramine in the treatment of inpatient depression : a multicenter trial<\/strong>
      \nAnn Clin Psychiatry<\/em> 5:199-207; 1993<\/li>\n
    81. Beasley C, Sayler M, Potvin J<\/span>
      \nFluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial<\/strong>
      \nIntl Clin Psychopharmacol<\/em> 8:143-149; 1993<\/li>\n
    82. Heiligenstein J, Beasley C, Potvin J<\/span>
      \nFluoxetine not associated with increased aggression in controlled clinical trials<\/strong>
      \nIntl Clin Psychopharmacol<\/em> 8:277-280; 1993<\/li>\n
    83. Beasley C, Potvin J<\/span>
      \nFluoxetine: activating and sedating effects<\/strong>
      \nIntl Clin Psychopharmacol<\/em> 8:271-275; 1993<\/li>\n
    84. Bergstrom R, Beasley C, Levy N, Blumenfield M, Lemberger L<\/span>
      \nA review of the effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and their risk-benefit profile of fluoxetine<\/strong>
      \nIntl Clin Psychopharmacology<\/em> 8:261-266; 1993<\/li>\n
    85. Beasley C, Masica D, Heiligenstein J, Wheadon D, Zerbe R<\/span>
      \nPossible monoamine oxidase inhibitor – serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings<\/strong>
      \nJ Clin Psychopharmacol<\/em> 13:312-320; 1993<\/li>\n
    86. Goldstein D, Rampey A, Potvin J, Masica D, Beasley C<\/span>
      \nAnalyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction<\/strong>
      \nJ Clin Psychiatry<\/em> 54:309-316; 1993<\/li>\n
    87. Heiligenstien J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D<\/span>
      \nFluoxetine not associated with increased violence or aggression in controlled clinical trials<\/strong>
      \nAnn Clin Psychiatry<\/em> 4:285-295; 1992<\/li>\n
    88. Beasley C, Sayler M, Weiss A, Potvin J<\/span>
      \nFluoxetine: activating and sedating effects at multiple fixed doses<\/strong>
      \nJ Clin Psychopharmacol<\/em> 12:328-333; 1992<\/li>\n
    89. Wheadon D, Rampey A, Thompson V, Potvin J, Masica D, Beasley C<\/span>
      \nLack of association between fluoxetine and suicidality in bulimia nervosa<\/strong>
      \nJ Clin Psychiatry<\/em> 53:235-241; 1992<\/li>\n
    90. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstein J, Thompson V, Murphy D, Masica D<\/span>
      \nFluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression<\/strong>
      \nIntl Clin Psychopharmacol<\/em> 6:Suppl 6:53-75; 1992<\/li>\n
    91. Beasley C, Masica D, Potvin J<\/span>
      \nFluoxetine: a review of receptor and functional effects and their clinical implications<\/strong>
      \nPsychopharmacology<\/em> 107:1-10; 1992<\/li>\n
    92. Beasley C, Potvin J, Masica D, Wheadon D, Dornseif B, Genduso L <\/span>
      \nFluoxetine: no association with suicidality in obsessive-compulsive disorder<\/strong>
      \nJ Affective Disorders<\/em> 24:1-10; 1992<\/li>\n
    93. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstien J, Thompson V, Murphy D, Masica D<\/span>
      \nFluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression<\/strong>
      \nBMJ<\/em> 303:685-692; 1991<\/li>\n
    94. Beasley C, Poltz J, Dornseif B, Bosomworth J, Sayler M<\/span>
      \nFluoxetine versus trazodone: efficacy and activating-sedating effects<\/strong>
      \nJ Clin Psychiatry<\/em> 52:294-99; 1991<\/li>\n
    95. Beasley C, Sayler M, Bosomworth J, Wernicke J<\/span>
      \nHigh-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression<\/strong>
      \nJ Clin Psychopharmacol<\/em> 11:166-174; 1991<\/li>\n
    96. Usher R, Beasley C, Bosomworth J<\/span>
      \nEfficacy and safety of morning versus evening fluoxetine administration<\/strong>
      \nJ Clin Psychiatry<\/em> 52:134-136; 1991<\/li>\n
    97. Beasley C, Sayler M, Cunningham G, Weiss A, Masica D<\/span>
      \nFluoxetine in tricyclic refractory major depressive disorder<\/strong>
      \nJ Affective Disorders<\/em> 20:193-200; 1990<\/li>\n
    98. Beasley C, Bosomworth J, Wernicke J<\/span>
      \nFluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression<\/strong>
      \nPsychopharm Bull<\/em> 26:18-24; 1990<\/li>\n
    99. McCombs J, Nichol M, Stimmel G, Sclar D, Beasley C, Gross L<\/span>
      \nThe cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population<\/strong>
      \nJ Clin Psychiatry<\/em> 51:6, suppl:60-69; 1990<\/li>\n
    100. Beasley C, Magnusson M, Garver D<\/span>
      \nTSH response to TRH and haloperidol response latency in psychoses<\/strong>
      \nBiol Psychiatry<\/em> 24:423-31; 1988<\/li>\n<\/ol>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n<\/div>
      \n\t
      \n\t\t
      <\/div>\n
      \n\t\t
      \n\t\t\t

      LETTERS<\/h3>\n
        \n
      1. Beasley C <\/span>
        \nResponse (letter). Aust N Z J Psychiatry<\/em> 33:12-122; 1999.<\/li>\n<\/ol>\n
          \n
        1. Perry PJ, Sanger T, Beasley CM <\/span>
          \nPlasma olanzapine and clinical response (Response letter). J Clin Psychopharmacol<\/em> 19:193-194; 1999.<\/li>\n<\/ol>\n
            \n
          1. Beasley C <\/span>
            \nResponse (letter). Br J Psychiatry<\/em> 175:391-392; 1999.<\/li>\n<\/ol>\n
              \n
            1. Beasley C <\/span>
              \nResponse (letter). CNS Drugs<\/em> 9:513-515; 1998.<\/li>\n<\/ol>\n
                \n
              1. Beasley C <\/span>
                \nResponse (letter). Neuropsychopharmacol<\/em> 16:89-90; 1997.<\/li>\n<\/ol>\n
                  \n
                1. Beasley C <\/span>
                  \nFluoxetine-Dopaminergic\u00a0Interaction Data (letter). J Clin Psychiatry<\/em> 55:77-78; 1994.<\/li>\n<\/ol>\n
                    \n
                  1. Masica D, Beasley C, Kotsanos J, Potvin J <\/span>
                    \nTrend in suicide rates since fluoxetine introduction (letter). Am J Pub Health<\/em> 82:1295; 1992.<\/li>\n<\/ol>\n
                      \n
                    1. Beasley C <\/span>
                      \nReply (letter). J Clin Psychopharmacol<\/em> 12:220-221; 1992.<\/li>\n<\/ol>\n
                        \n
                      1. Beasley C <\/span>
                        \nFluoxetine and suicide (letter). BMJ<\/em> 303:1200; 1991.<\/li>\n<\/ol>\n
                          \n
                        1. Fuller R, Beasley C <\/span>
                          \nFluoxetine: mechanism of action (letter). J Am Acad Child Adolesc\u00a0Psychiatry<\/em> 30:849-850; 1991.<\/li>\n<\/ol>\n
                            \n
                          1. Beasley C <\/span>
                            \nCorrection to \u2018Fluoxetine Overdose: A Case Report\u2019 (letter). J Anal Tox<\/em> 14:63; 1990.<\/li>\n<\/ol>\n\n\t\t<\/div> \n\t<\/div>
                            <\/div>\n
                            \n\t\t
                            \n\t\t\t

                            ABSTRACTS and POSTERS (selected)<\/h3>\n
                              \n
                            1. Camporeale A, Beasley C, Tanaka Y, D’Souza D, Upadhyaya H<\/span>
                              \nChanges in blood pressure and heart rate associated with atomoxetine treatment in attention-deficit\/hyperactivity disorder<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 22:429-430; 2012.<\/li>\n
                            2. Gatz JL, Jamal HH, Plewes JM, Case MG, Beasley CM<\/span>
                              \nTreatment-resistant major depressive disorder: comparison of acute (2-week) safety endpoints after switching treatment from other antidepressants to olanzapine\/fluoxetine combination therapy<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0Holywood, FL,\u00a0Dec.\u00a07, 2009.<\/li>\n
                            3. Beasley CM, Disch D, Chen W, Witte M, Acharya N, Perahia D, Nilsson, M, Perlis R<\/span>
                              \nPotential risk factors for development of treatment-emergent suicidal ideation in the duloxetine placebo-controlled major depressive disorder database<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0Boca Raton, FL,\u00a0Dec.\u00a012, 2007.<\/li>\n
                            4. Beasley CM, Disch D, Prabhakar V, Desiah D, Tamura R, Perlis R<\/span>
                              \nPotential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database<\/strong>
                              \nNeuropsychopharmacol<\/em> 31:S1:100-101; 2006.<\/li>\n
                            5. Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM, Baldessarini RJ<\/span>
                              \nDuloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major depressive disorder<\/strong>
                              \nNeuropsychopharmacol<\/em> 30:S1:S97; 2005.<\/li>\n
                            6. Beasley CM, Sutton VK, Taylor C, Sethuraman G, Dossenbach M, Naber D, Pickar D<\/span>
                              \nDoes maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?<\/strong>
                              \nNeuropsychopharmacol<\/em> 30:S1:S189; 2005.<\/li>\n
                            7. Beasley C, Stauffer V, Liu-Seifert H, Rock S, Mitchell C, Dunayevich E, Davis J, Breier A<\/span>
                              \nOverall treatment effectiveness as measured by time continuing on antipsychotic therapy<\/strong>
                              \nNeuropsychopharmacol<\/em> 29:S1:S106; 2004.<\/li>\n
                            8. Beasley C, Acharya N, Polzer J, Nilsson M, Rosen A, Cavazzoni P<\/span>
                              \nNomenclature for suicide-related thoughts and behaviors<\/strong>
                              \nAmerican Academy of Child and Adolescent Psychiatry.\u00a0Washington, DC, Oct. 21, 2004.<\/li>\n
                            9. Beasley CM, Sowell MO, Carlson C, Mukhnopadhyay N, Dannanberg j, Henry R, Breier A, Cavazzoni P<\/span>
                              \nProspective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo<\/strong>
                              \nSchizophrenia Res<\/em> 60:309, 2003.<\/li>\n
                            10. Beasley C, Sowell M, Henry R, Carlson C, Mukhopadhyay N, Dananberg J, Cavazzoni P, Breier A<\/span>
                              \nProspective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone, or placebo<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 11, 2002.<\/li>\n
                            11. Czekalla J, Beasley C, David S, Berg P, Stauffer V, Boylan C<\/span>
                              \nCardiac conduction in females under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 12:S3:S291-292; 2002.<\/li>\n
                            12. Tohen\u00a0 M, David RS, Beasley CM, Alaka K<\/span>
                              \nQT intervals: IM olanzapine treatment in acutely agitated patients<\/strong>
                              \nEuropean Psychiatry <\/em>17:105; 2002.<\/li>\n
                            13. Beasley C, Sowell M, Cavazzoni P, Breier A, Steinberg H, Dananberg J<\/span>
                              \nAssessment of insulin secretory responses using the hyperglycemic clamp in normal subjects treated with olanzapine, risperidone, or placebo
                              \n<\/strong>Annual Meeting of the American College of Neuropsychopharmacology
                              \nKona, HA, Dec. 10, 2001.<\/li>\n
                            14. Beasley CM, Hamilton SH, Dossenbach M<\/span>
                              \nRelapse prevention with olanzapine<\/strong>
                              \nSchizophrenia Res <\/em>41:196-197; 2000.<\/li>\n
                            15. Czekalla J, Dellva MA, Berg PH, Grundy SL, Beasley CM<\/span>
                              \nCardiac safety profile of olanzapine based on preclinical and clinical ECG data<\/strong>
                              \nSchizophrenia Res <\/em>41:195; 2000.<\/li>\n
                            16. Beasley C, Berg P, Dananberg J, Kwong K, Taylor C, Breier A<\/span>
                              \nIncidence and rate of treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR, Dec. 11, 2000.<\/li>\n
                            17. Jones B, Wang H, David S, Nisivoccia J, Beasley C, Feldman P, Meehan K<\/span>
                              \nA double-blind, placebo controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR, Dec. 13, 2000.<\/li>\n
                            18. Beasley CM, Hamilton SH, Dossenbach M<\/span>
                              \nRelapse prevention with olanzapine<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 10:304; 2000.<\/li>\n
                            19. Crumb W, Beasley C, Thornton A, Breier A<\/span>
                              \nCardiac ion channel blocking profile of olanzapine and other antipsychotics<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0Alcapulco, Mexico, Dec. 13, 1999.<\/li>\n
                            20. Tran PV, Basson BR, Kennedy JS, Beasley CM, Bymaster FP, Tollefson GD<\/span>
                              \nThe comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 9:290-291; 1999.<\/li>\n
                            21. Schmidt M, Michelson D, Beasley CM, Kopp J, Koke S<\/span>
                              \nLong term treatment outcomes of highly anxious depressed patients: evidence from a 52-week trial with fluoxetine<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 9:209; 1999.<\/li>\n
                            22. Basson B, Kennedy J, Tran P, Beasley C, Bymaster F, Tollefson G<\/span>
                              \nThe comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis<\/strong>
                              \nAnnual meeting of the American College of Neuropsychopharmacology.\u00a0Las Croabas, Puerto Rico, PR, Dec. 15, 1998.<\/li>\n
                            23. Beuzen J, Birkett M, Kiesler G, Tollefson G, Wood A, Beasley C<\/span>
                              \nOlanzapine vs
                              \nclozapine: an international double-blind study in treatment resistant schizophrenia<\/strong>
                              \nAnnual meeting of the American College of Neuropsychopharmacology.\u00a0Las Croabas, PR, Dec. 16, 1998.<\/li>\n
                            24. Tamura R, Michelson D, Sundell K, Beasley C<\/span>
                              \nAdverse event profiles associated with long-term fluoxetine treatment<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Toronto, Canada, June 3, 1998.<\/li>\n
                            25. Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H<\/span>
                              \nThe differential risk of tardive dyskinesia with olanzapine<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Toronto, Canada, June 2, 1998.<\/li>\n
                            26. Wright P, Tollefson G, Beasley C, Tamura R, Tran P, Potvin J<\/span>
                              \nA blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol<\/strong>
                              \nSchizophrenia Res<\/em> 29:206; 1998.<\/li>\n
                            27. Jones B, Crawford A, Beasley C, Tollefson G<\/span>
                              \nThe acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration<\/strong>
                              \nSchizophrenia Res<\/em> 29:204-205; 1998.<\/li>\n
                            28. Tamura R, Beasley C, Dellva M, Glazer W, Morgenstern H, Tollefson G<\/span>
                              \nWhat is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?<\/strong>
                              \nSchizophrenia Res<\/em> 29:176; 1998.<\/li>\n
                            29. Reams S, Sanger T, Beasley C<\/span>
                              \nOlanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders<\/strong>
                              \nSchizophrenia Res<\/em> 29:151-152, 1998.<\/li>\n
                            30. Tran P, Lu Y, Sanger T, Beasley C, Tollefson G<\/span>
                              \nOlanzapine in the treatment of schizoaffective disorder<\/strong>
                              \nSchizophrenia Res<\/em> 29:151; 1998.<\/li>\n
                            31. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD<\/span>
                              \nThe influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia<\/strong>
                              \nSchizophrenia Res<\/em> 29:28; 1998.<\/li>\n
                            32. Tollefson G, Sanger T, Beasley C<\/span>
                              \nA blinded trial on the course and relationship of depressive symptoms in schizophrenia<\/strong>
                              \nAnnual meeting of the American College of Neuropsychopharmacology.\u00a0Kona, HA, Dec. 8, 1997.<\/li>\n
                            33. Tran P, Tollefson G, Beasley C, Crawford A<\/span>
                              \nFrom molecule to marketplace: profile of the atypical antipsychotic olanzapine<\/strong>
                              \nAnnual meeting of the American College of Neuropsychopharmacology.\u00a0Kona, HA, Dec. 10, 1997.<\/li>\n
                            34. Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H<\/span>
                              \nWhat is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?<\/strong>
                              \nAnnual meeting of the American College of Neuropsychopharmacology.\u00a0Kona, HA, Dec. 10, 1997.<\/li>\n
                            35. Dellva M, Tamura R, Glazer W, Morgenstern H, Beasley C<\/span>
                              \nWhat is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 7:199-200; 1997.<\/li>\n
                            36. Crawford A, Beasley C, Tollefson G<\/span>
                              \nThe acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 7:199; 1997.<\/li>\n
                            37. Crawford A, Gomez J, Beasley C, Tollefson G<\/span>
                              \nOlanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial<\/strong>
                              \nEuro Neuropsychopharmacol 7<\/em>:199; 1997.<\/li>\n
                            38. Conley R, Tamminga C, Beasley C<\/span>
                              \nOlanzapine vs. Chlorpromazine in treatment resistant schizophrenia<\/strong>
                              \nAnnual meeting of the American College of Neuropsychopharmacology. San Juan, PR; Dec. 12, 1996.<\/li>\n
                            39. Tran P, Dellva M, Rampey V, Tollefson G, Beasley C<\/span>
                              \nLong-term continuation therapy with the novel antipsychotic olanzapine: a review of the clinical experience<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 6:115; 1996.<\/li>\n
                            40. Kuntz A, Tran P, Dellva M, Sanger T, Beasley C, Tollefson G<\/span>
                              \nAcute phase efficacy and safety of olanzapine: a review<\/strong>
                              \nEuro Neuropsychopharmacol<\/em>\u00a06:115; 1996.<\/li>\n
                            41. Dellva M, Satterlee W, Tran P, Beasley C, Greaney M, Tollefson G<\/span>
                              \nExtrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment<\/strong>
                              \nEuro Neuropsychopharmacol<\/em>\u00a06:106; 1996.<\/li>\n
                            42. Lu Y, Sanger T, Beasley C, Tran P, Tollefson G<\/span>
                              \nOlanzapine in the treatment of schizoaffective disorder<\/strong>
                              \nEuropean Neuropsychopharmacology<\/em>\u00a06:106; 1996.<\/li>\n
                            43. Tollefson G, Sanger T, Beasley C<\/span>
                              \nThe course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the atypical antipsychotic olanzapine<\/strong>
                              \nEuro Neuropsychopharmacol<\/em>\u00a06:14; 1996.<\/li>\n
                            44. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S<\/span>
                              \nOlanzapine versus placebo, results of the United States double-blind olanzapine trial<\/strong>
                              \nEuro Neuropsychopharmacol<\/em>\u00a06:58; 1996.<\/li>\n
                            45. Quicken FM, Stewart JW, McGrath PJ, Beasley C<\/span>
                              \nPattern analysis predicts relapse on fluoxetine and placebo during continuation<\/strong>
                              \nEuro Neuropsychopharmacol<\/em>\u00a06:153-154; 1996.<\/li>\n
                            46. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S,Van Ostrand R, Paul S<\/span>
                              \nAcute and long-term results of the North American double-blind olanzapine trial<\/strong>
                              \nEuro Neuropsychopharmacol<\/em>\u00a06:59; 1996<\/li>\n
                            47. Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C<\/span>
                              \nQuality of life outcomes of olanzapine, a new atypical antipsychotic agent<\/strong>
                              \nSchizophrenia Res<\/em> 18:130-131; 1996.<\/li>\n
                            48. Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM, Wood A, Beuzen JN<\/span>
                              \nOlanzapine versus haloperidol: results of the multi-center international trial<\/strong>
                              \nSchizophrenia Res<\/em> 18:131; 1996.<\/li>\n
                            49. Tran P, Dellva M, Street J, Beasley C, Tollefson G, Kiesler G<\/span>
                              \nExtrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatments<\/strong>
                              \nWorld Congress of Psychiatry.\u00a0Madrid, Spain; Aug. 26, 1996.<\/li>\n
                            50. Dellva M, Tran P, Beasley C, Cousins L, Krueger J, Tollefson G<\/span>
                              \nClinical experience with long-term continuation treatment with olanzapine<\/strong>
                              \nWorld Congress of Psychiatry.\u00a0Madrid, Spain; Aug. 25, 1996.<\/li>\n
                            51. Beasley C<\/span>
                              \nOlanzapine safety overview<\/strong>
                              \nWorld Congress of Psychiatry.\u00a0Madrid, Spain, Aug. 23, 1996.<\/li>\n
                            52. Tollefson G, Sanger T, Beasley C<\/span>
                              \nThe course of primary and secondary negative symptoms in a controlled trial with olanzapine<\/strong>
                              \nCINP.\u00a0Melbourne, Australia, June 26, 1996.<\/li>\n
                            53. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, Paul S<\/span>
                              \nAcute and long-term results of the North American double-blind olanzapine trial<\/strong>
                              \nCINP.\u00a0Melbourne, Australia, June 25, 1996.<\/li>\n
                            54. Tran P, Beasley C, Street J, Tamura R, Dellva M, Graffeo K, Kruger J, Tollefson G<\/span>
                              \nOlanzapine versus haloperidol: acute results of the multi-center international trail<\/strong>
                              \nCINP.\u00a0Melbourne, Australia, June 25, 1996.<\/li>\n
                            55. Beasley C, Tran P, Beuzen J, Tamura R, Dellva M, Bailey J, Kruger J, Tollefson G<\/span>
                              \nOlanzapine versus haloperidol: long-term results of the international trial<\/strong>
                              \nCINP.\u00a0Melbourne, Australia, June 25, 1996.<\/li>\n
                            56. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S<\/span>
                              \nOlanzapine versus placebo, results of the United States double-blind olanzapine trial<\/strong>
                              \nCINP.\u00a0Melbourne, Australia, June 25, 1996.<\/li>\n
                            57. Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J, Wood A, Graffeo K, Meltzer H<\/span>
                              \nOlanzapine in the treatment of schizophrenia and other psychotic disorders<\/strong>
                              \nNCDEU Annual Meeting.\u00a0Boca Raton, FL, May 24, 1996.<\/li>\n
                            58. Satterlee W, Beasley C, Sanger T, Tollefson G<\/span>
                              \na clinical update on olanzapine: atypical antipsychotic<\/strong>
                              \nNCDEU Annual Meeting.\u00a0Boca Raton, FL, May 23, 1996.<\/li>\n
                            59. Crawford A, Beasley C, Tollefson G<\/span>
                              \nOlanzapine: impact of an atypical antipsychotic candidate on prolactin release<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0New York, NY, May 9, 1996.<\/li>\n
                            60. Patel B, Kurtz D, Callaghan J, Beasley C, Bergstrom R<\/span>
                              \nEffect of smoking and gender on population pharmacokinetics of olanzapine<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0New York, NY, May 8, 1996.<\/li>\n
                            61. Tran P, Dellva M, Beasley C, Satterlee W, Cousins L, Tollefson G<\/span>
                              \nClinical experience with long-term continuation treatment with olanzapine<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0New York, NY, May 8, 1996.<\/li>\n
                            62. Satterlee W, Beasley C, Tran P, Tamura R, Krueger J, Tollefson G<\/span>
                              \nOlanzapine versus haloperidol: results of a large multicenter international trial<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0New York, NY, May 8, 1996.<\/li>\n
                            63. Tollefson G, Sanger T, Beasley C<\/span>
                              \nThe course of primary and secondary negative symptoms in a controlled trial with olanzapine<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0New York, NY, May 8, 1996.<\/li>\n
                            64. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T<\/span>
                              \nOlanzapine: molecule to drug candidate<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0New York, NY, May 7, 1996.<\/li>\n
                            65. Beasley C, Tran P, Tamura R, Tollefson G<\/span>
                              \nOlanzapine versus haloperidol: results of the multi-center international trial<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR, Dec. 15, 1995.<\/li>\n
                            66. Tran P, Beasley C, Dellva M, Cousins L, Gusman S, Tollefson G<\/span>
                              \nLong-term efficacy and safety of olanzapine<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR Dec. 13, 1995.<\/li>\n
                            67. Tran P, Beasley C, Crawford A, Hamilton S, Tollefson G<\/span>
                              \nAcute and long-term results of the North American double-blind olanzapine trial<\/strong>
                              \nBelgian College of Neuropsychopharmacology and Biological Psychiatry (BCNBP).\u00a0Kortenberg, Belgium, Dec. 1, 1995.<\/li>\n
                            68. Tollefson G, Beasley C, Tran P, Sanger T<\/span>
                              \nOlanzapine: an exciting atypical antipsychotic-the clinical experience<\/strong>
                              \nEuropean College of Neuropsychopharmacology Annual Meeting.\u00a0Venice, Italy, Oct. 1, 1995.<\/li>\n
                            69. Dittmann R, Beasley C, Geuppert M, Muhlenbacher<\/span>
                              \nClinical efficacy and safety of olanzapine: results from a double blind-multinational trial<\/strong>
                              \nPharmacopsychiatry<\/em> 28:172; 1995.<\/li>\n
                            70. Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T, Hamilton S<\/span>
                              \nClinical efficacy and safety of increasing doses of olanzapine, a new \u201catypical\u201d antipsychotic agent<\/strong>
                              \nCINP Regional Conference.\u00a0Vienna, Austria and Prague, Czech Republic, June 10, 1995.<\/li>\n
                            71. Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T<\/span>
                              \nClinical efficacy and safety of olanzapine, a new \u201catypical\u201d antipsychotic agent<\/strong>
                              \nCINP Regional Conference.\u00a0Vienna, Austria and Prague, Czech Republic, June 10, 1995.<\/li>\n
                            72. Beuzen J, Beasley C, Tran P, Sanger T, Paul S, Tollefson G<\/span>
                              \nAdditional clinical experience with olanzapine, an \u201catypical\u201d antipsychotic<\/strong>
                              \nCINP Regional Conference.\u00a0Vienna, Austria and Prague, Czech Republic, June 10, 1995.<\/li>\n
                            73. Tran P, Beasley C, Tollefson G, Crawford A, Paul S<\/span>
                              \nOlanzapine: an update on recent clinical studies<\/strong>
                              \nNCDEU Annual Meeting.\u00a0Orlando, FL, June 1, 1995.<\/li>\n
                            74. Tollefson G, Beasley C, Tran P, Satterlee W, Lu Y, Mesters P, Gomez J, Dittman R, Beuzen J, Graffeo K, Kolling C, Paul S<\/span>
                              \nOlanzapine in the treatment of schizophrenia and other psychotic disorders<\/strong>
                              \nNCDEU Annual Meeting.\u00a0Orlando, FL, May 31, 1995.<\/li>\n
                            75. Tollefson G, Beasley C, Tran P, Sanger T<\/span>
                              \nThe next generation of antipsychotics<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Miami, FL, May 24, 1995.<\/li>\n
                            76. Satterlee W, Beasley C, Sanger T, Tollefson G<\/span>
                              \nAdditional clinical experience with olanzapine, an atypical antipsychotic<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Miami, FL, May 24, 1995.<\/li>\n
                            77. Tran P, Beasley C, Tollefson G, Blin O, Hamilton S, Wharton I, Cousins L, Kiesler G, Greaney M, Gussman S<\/span>
                              \nClinical efficacy and safety of increasing doses of olanzapine: a new \u201catypical\u201d antipsychotic agent<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Miami, FL, May 23, 1995.<\/li>\n
                            78. Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J, Graffeo K, Wood A, Meltzer H<\/span>
                              \nOlanzapine in the treatment of schizophrenia and other psychotic disorders<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Miami, FL, May 23, 1995.<\/li>\n
                            79. Beasley C, Tran P, Tollefson G, Satterlee W, Crawford A, Wharton I, Luttman C, Voegele T<\/span>
                              \nLong-term efficacy and safety of olanzapine: a novel \u201catypical\u201d antipsychotic agent<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Miami, FL, May 23, 1995.<\/li>\n
                            80. Beasley C, Tollefson G, Tran P, Satterlee W<\/span>
                              \nOlanzapine: a potential atypical antipsychotic<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Miami, FL, May 23, 1995.<\/li>\n
                            81. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W<\/span>
                              \nOlanzapine: a promising \u201catypical\u201d antipsychotic agent<\/strong>
                              \nSchizophrenia Res<\/em> 15:169; 1995.<\/li>\n
                            82. Saterlee W, Beasley C, Sanger T, Tollefson G<\/span>
                              \nAdditional clinical experiences with olanzapine an \u201catypical\u201d antipsychotic<\/strong>
                              \nSchizophrenia Res<\/em> 15:163; 1995.<\/li>\n
                            83. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G<\/span>
                              \nOlanzapine a new \u201catypical\u201d antipsychotic<\/strong>
                              \nSchizophrenia Res<\/em> 15:163-164; 1995.<\/li>\n
                            84. Tollefson G, Sanger T, Beasley C, Tran P<\/span>
                              \nIs there a relationship between EPSE and efficacy: fact or fiction<\/strong>
                              \nScientific Council of the International Academy for Biomedical and Drug Research. Florence, Italy, Mar. 11, 1995.<\/li>\n
                            85. Beuzen J, Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G<\/span>
                              \nAdditional clinical experience with olanzapine, an \u201cAtypical\u201d Antipsychotic<\/strong>
                              \nCritical Issues in the Treatment of Schizophrenia Workshop.\u00a0Florence, Italy, Mar. 11, 1995.<\/li>\n
                            86. Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S<\/span>
                              \nAcute and long-term results of the North American double-blind olanzapine trial<\/strong>
                              \nEuro Neuopsychopharmacol 5:347-348; 1995<\/em>.<\/li>\n
                            87. Amsterdam JD, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW, Beasley CM<\/span>
                              \nFluoxetine and norfluoxetine levels in major depression<\/strong>
                              \nBiological Psychiatry 37:606; 1995<\/em>.<\/li>\n
                            88. Tollefson GD, Beasley CM, Tran PV, Sanger T<\/span>
                              \nOlanzapine: a novel antipsychotic with broad spectrum profile<\/strong>
                              \nBiological Psychiatry 35:746-747; 1994.<\/em><\/li>\n
                            89. Tran P, Beasley C, Satterlee W
                              \nSanger T, Holman S, Tollefson G<\/span>
                              \nOlanzapine: a potential novel antipsychotic agent<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR, Dec. 14, 1994.<\/li>\n
                            90. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W<\/span>
                              \nOlanzapine: a promising \u201catypical\u201d antipsychotic agent<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR, Dec. 14, 1994.<\/li>\n
                            91. Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G<\/span>
                              \nAdditional clinical experiences with olanzapine an \u201catypical\u201d antipsychotic<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR,\u00a0Dec. 14, 1994.<\/li>\n
                            92. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G<\/span>
                              \nOlanzapine a new \u201catypical\u201d antipsychotic<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan. Dec. 14, 1994.<\/li>\n
                            93. Tran P, Beasley C, Tollefson G, Holman S<\/span>
                              \nClinical efficacy and safety of olanzapine: a novel antipsychotic agent<\/strong>
                              \nEuropean College of Neuropsychopharmacology Annual Meeting.\u00a0Jerusalem, Israel, Oct. 18, 1994.<\/li>\n
                            94. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W<\/span>
                              \nOlanzapine: a promising \u201catypical\u201d antipsychotic agent<\/strong>
                              \nEuropean College of Neuropsychopharmacology Annual Meeting.\u00a0Jerusalem, Israel, Oct. 18, 1994.<\/li>\n
                            95. Wood A, Beasley C, Tollefson G, Tran P<\/span>
                              \nEfficacy of olanzapine in the positive and negative symptoms of schizophrenia<\/strong>
                              \nEuro Neuropsychopharmacol<\/em> 4:224; 1994.<\/li>\n
                            96. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T<\/span>
                              \nOlanzapine: a promising \u201catypical\u201d antipsychotic agent<\/strong>
                              \nPlan Asian-Pacific Conference on Mental Health.\u00a0Beijing, China, Oct. 12, 1994.<\/li>\n
                            97. Tran P, Beasley C, Tollefson G, Satterlee W, Sanger T<\/span>
                              \nClinical efficacy and safety of olanzapine: a potential atypical antipsychotic agent<\/strong>
                              \nPan Asian-Pacific Conference on Mental Health.\u00a0Beijing, China, Oct 12, 1994.<\/li>\n
                            98. Satterlee W, Beasley C, Sanger T,\u00a0Tollefson G<\/span>
                              \nA clinical update on olanzapine, an \u201catypical\u201d antipsychotic<\/strong>
                              \nInstitute on Hospital and Community Psychiatry Annual Meeting.\u00a0San Diego, CA, Oct. 3, 1994.<\/li>\n
                            99. Satterlee W, Beasley C, Tollefson G, Moore N, Tran P, Sanger T<\/span>
                              \nPreclinical and clinical observations of olanzapine (a new antipsychotic agent)<\/strong>
                              \nSchizophrenia 1994: 3rd<\/sup> International Conference.\u00a0Vancouver, Canada, Aug. 23, 1994.<\/li>\n
                            100. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W<\/span>
                              \nClinical efficacy and safety of olanzapine, a new atypical antipsychotic agent<\/strong>
                              \nNeuropsychopharmacol<\/em> 10:3S, Part 2:267S; 1994.<\/li>\n
                            101. Beasley C, Tollefson G, Moore N, Tye N<\/span>
                              \nOlanzapine: the new \u201catypical\u201d antipsychotic agent<\/strong>
                              \nNeuropsychopharmacol<\/em> 10:3S, Part 1:536S; 1994.<\/li>\n
                            102. Satterlee W, Beasley C, Tollefson G, Moore N, Tran P<\/span>
                              \nPreclinical and clinical observations of olanzapine (a new antipsychotic)<\/strong>
                              \nNCDEU Annual Meeting.\u00a0Marco Island, FL, June 2, 1994.<\/li>\n
                            103. Rosenbaum J, Fava M, Quitkin F, Fawcett J, Amsterdam J, Reimherr F, Beasley C<\/span>
                              \nTime to remission of depression with acute fluoxetine treatment<\/strong>
                              \nNCDEU Annual Meeting.\u00a0Marco Island, FL, June 2, 1994.<\/li>\n
                            104. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W<\/span>
                              \nClinical efficacy and safety of olanzapine, a new atypical antipsychotic agent<\/strong>
                              \nCanadian College of Neuropsychopharmacology Annual Meeting. Montreal, Canada, May 31, 1994.<\/li>\n
                            105. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W<\/span>
                              \nClinical efficacy and safety of olanzapine: a new atypical Antipsychotic agent<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Philadelphia, PA, May 24, 1994.<\/li>\n
                            106. Beasley C, Tollefson G, Tran P, Satterlee W<\/span>
                              \nOlanzapine: a potential atypical antipsychotic<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Philadelphia, PA, May 24, 1994.<\/li>\n
                            107. Beasley C, Tollefson G, Moore N<\/span>
                              \nOlanzapine: a new \u201catypical\u201d antipsychotic agent<\/strong>
                              \nEighth Triannual Congress of the Israel Psychiatric Association. Tiberias, Israel, May 3, 1994.<\/li>\n
                            108. Rosenbaum J, Quitkin F, Fava M, Amsterdam J, Fawcett J, Zajecka J, Lebegue B, Reimherr F, Beasley C<\/span>
                              \nFluoxetine vs. Placebo: long-term treatment of MDD<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0Honolulu, HA, Dec. 15, 1993.<\/li>\n
                            109. Beasley C, Tollefson G, Tye N, Moore N<\/span>
                              \nOlanzapine: a potential \u201catypical\u201d antipsychotic agent<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0Honolulu, HA, Dec. 15, 1993.<\/li>\n
                            110. Sayler M, Pande A, Beasley C, Tollefson G<\/span>
                              \nAntidepressant efficacy and severity of depression<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0San Francisco, CA, May 26, 1993.<\/li>\n
                            111. Tye N, Moore N, Rees G, Sanger G, Calligaro D, Beasley C<\/span>
                              \nPreclinical pharmacology of olanzapine: a novel \u2018atypical\u2019 antipsychotic agent<\/strong>
                              \nSecond International Conference on Schizophrenia.\u00a0Vancouver, Canada, July 21, 1992.<\/li>\n
                            112. Beasley C, Montgomery S, Tye N<\/span>
                              \nOlanzapine: an open-label study in schizophrenia<\/strong>
                              \nSecond International Conference on Schizophrenia.\u00a0Vancouver, Canada, July 21, 1992.<\/li>\n
                            113. Beasley C, Sayler M<\/span>
                              \nFluoxetine: activating and sedating effects at multiple fixed doses<\/strong>
                              \nCINP.\u00a0Nice, France, June 29, 1992.<\/li>\n
                            114. Bergstrom R, Beasley C, Levy N, Dubey A, Blumenfield M, Goodman A, Solomon R<\/span>
                              \nFluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely impaired renal function<\/strong>
                              \nPharmaceutical Research<\/em> 8:S294; 1991.<\/li>\n
                            115. Heiligenstein J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D<\/span>
                              \nFluoxetine not associated with violent behavior in controlled clinical trials<\/strong>
                              \nClinical Research<\/em> 39:768A; 1991.<\/li>\n
                            116. Beasley C, Faries D, Sayler M, Potvin J<\/span>
                              \nFluoxetine not associated with suicidality in international controlled clinical trials in depression<\/strong>
                              \nClinical Research<\/em> 39:767A; 1991.<\/li>\n
                            117. McDermott B, Beasley C, Kelly K, Hirschowitz J, Garver D<\/span>
                              \nConfounds of neuroendocrine challenge tests<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Montreal, Canada, May 10, 1988.<\/li>\n
                            118. Garver D, Beasley C, Kelly K, Magnusson M, Johnson C, Chopra Y<\/span>
                              \nAntipsychotic response latencies: separate diseases<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Montreal, Canada, May 9, 1988.<\/li>\n
                            119. Garver D, Beasley C, Sautter F, Chopra Y<\/span>
                              \nEarly antipsychotic response with neuroleptics and dopamine psychosis<\/strong>
                              \nAnnual Meeting of the American College of Neuropsychopharmacology.\u00a0San Juan, PR, Dec. 8, 1987.<\/li>\n
                            120. Sautter F, McDermott B, Beasley C<\/span>
                              \nShort-term outcome of schizophreniform disorder<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Chicago, IL, May 12, 1987.<\/li>\n
                            121. Beasley C, Garver D<\/span>
                              \nGrowth hormone response and neuroleptic response in neuroleptic na\u00efve patients<\/strong>
                              \nAmerican Psychiatric Association Annual Meeting.\u00a0Chicago, IL, May 12, 1987.<\/li>\n
                            122. Beasley C, Magnusson M, Garver D<\/span>
                              \nTSH response to TRH and\u00a0haloperidol response latency in psychoses<\/strong>
                              \nSociety for Biological Psychiatry Annual Meeting.\u00a0Chicago, IL, May 7, 1987.<\/li>\n<\/ol>\n\n\t\t<\/div> \n\t<\/div>
                              <\/div>\n
                              \n\t\t
                              \n\t\t\t

                              GRANT REPORTS<\/h3>\n
                                \n
                              1. Anderson J, Kline P, Beasley C<\/span>
                                \nA theory of the acquisition of cognitive skills<\/strong>
                                \nTechnical Report 77-1. Yale University, 1978<\/li>\n
                              2. Anderson J, Kline P, Beasley C<\/span>
                                \nComplex learning processes<\/strong>
                                \nTechnical Report 78-1. Yale University, 1978<\/li>\n<\/ol>\n\n\t\t<\/div> \n\t<\/div>
                                <\/div>\n
                                \n\t\t
                                \n\t\t\t

                                PATENTS ISSUED<\/h3>\n

                                5605897\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 2-Methyl-Thieno-Benzodiazepine (Olanzapine)
                                \n5817656\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method for Treating Mental Disorders (Olanzapine)
                                \n5817657\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method for Treating Psychoactive Substance Disorders (Olanzapine)
                                \n5776928\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method for Treating Dyskinesia (Olanzapine)
                                \n6071902\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method for Treating Excessive Aggression (Olanzapine)
                                \n6159963\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method for Treating Substance Abuse (Olanzapine)
                                \n6274636\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method of Treating Tic Disorder (Olanzapine)
                                \n6506746\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Method for Treating Cognitive Dysfunction (Olanzapine)<\/p>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n<\/div>

                                \n\t
                                \n\t\t\n\t<\/div> \n<\/div>\n","protected":false},"excerpt":{"rendered":"BOOK CHAPTERS Beasley C, Grundy S, Gannon K, Berg P Overview of the safety of olanzapine In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.) Olanzapine (Zyprexa): A Novel Antipsychotic Philadelphia: Lippincott Williams & Wilkins, 2000 Tran P. Sutton V, Beasley C, Tollefson G Efficacy of olanzapine In Tran P, [...]","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages\/369"}],"collection":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=369"}],"version-history":[{"count":2,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages\/369\/revisions"}],"predecessor-version":[{"id":395,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages\/369\/revisions\/395"}],"wp:attachment":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}